中文

IgMaxTM
IgM advantage
First immune response upon infection
Naturally occurring in mucosa
Have 10 binding sites (pentameric)
Stronger virus neutralizing efficacy than IgG
Stronger complement activation
IgM could be an attractive development target when “stopping the infection at the gate”


Overcoming CMC challenges of IgM


Problem description

Canton Biologics solution

IgM titers are far below the benchmark of IgG molecules

Canton Biologics Cell Line and Vector Technology

Hexamers impurities in addition to naturally pentameric IgM  

Ratio optimization of the involved chains

IgM exhibits lower binding to affinity chromatography compared to IgG

Established a high yield DSP platform & replace AC in case of insufficient binding

Complexity and size of the molecule

Profound understanding of broad method portfolio

Many disulfide bond and free cysteins

Advanced MS-MS for characterization

IgM is more prone to aggregation

Efficient platform formulation + optimization

Long out-of-fridge and preservative

Experienced formulation development team

IgM Formulation IgM
Simple stable formulation for complicated, unstable IgM molecule
Formulation: buffer + stabilizer+ isotonic agent